Adjunctive therapy for asthma: Treatment options

American Journal of Managed Care

Volumn 6, Issue 7 SUPPL., 2000, Pages

  Nathan, Robert A ^a,b  

^a UNIVERSITY OF COLORADO   (United States)

^b Asthma & Allergy Associates PC and Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE DIPROPIONATE; BUDESONIDE; CORTICOSTEROID; FLUTICASONE; FORMOTEROL; LEUKOTRIENE RECEPTOR AFFECTING AGENT; SALMETEROL; THEOPHYLLINE; ZAFIRLUKAST;

ADD ON THERAPY; ADJUVANT THERAPY; ASTHMA; CONFERENCE PAPER; DISEASE COURSE; DISEASE EXACERBATION; MUSCLE DISEASE; PRIORITY JOURNAL; RESPIRATORY TRACT INFLAMMATION; SMOOTH MUSCLE;

EID: 0034000202     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (36)

1. National Institutes of Health, National Heart, Lung, and Blood Institute. Expert Panel Report 2: Guidelines for the Diagnosis and Management of Asthma. Bethesda, MD: National Institutes of Health; 1997. Publication 97-4051.
2. Pedersen S, O'Byrne P. A comparison of the efficacy and safety of inhaled corticosteroids in asthma. Allergy 1997;52(suppl 39):1-34.
3. Bisgaard H. Use of inhaled corticosteroids in pediatric asthma. Pediatric Pulmonary Supplement 1997;15:27-33.
4. Rickard KA, Stempel DA. Asthma survey demonstrates that the goals of the NHLBI have not been accomplished [abstract]. J Allergy Clin Immunol 1999;103:S171. Abstract 655.
5. Greening AP, Ind PW, Northfield M, Shaw G, for the Allen & Hanburys Limited UK Study Group. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Lancet 1994;344:219-224.
6. Woolcock A, Lundback B, Ringdal N, Jacques LA. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am J Respir Crit Care Med 1996;153:1481-1488.
7. Condemi JJ, Goldstein S, Kalberg C, Yancey S, Emmett A, Rickard K, for the Salmeterol Study Group. The addition of salmeterol to fluticasone propionate versus increasing the dose of fluticasone propionate in patients with persistent asthma. Ann Allergy Asthma Immunol 1999;82:383-389.
8. Glaxo Wellcome Study RM 1998/001/31/00. Data on file.
9. Murray JJ, Church NL, Anderson WH, et al. Concurrent use of salmeterol with inhaled corticosteroids is more effective than inhaled corticosteroid dose increases. Allergy Asthma Proc 1999;20:173-180.
10. Pearlman DS, Stricker W, Weinstein S, et al. Inhaled salmeterol and fluticasone: A study comparing monotherapy and combination therapy in asthma. Ann Allergy Asthma Immunol 1999;82:257-265.
11. Baraniuk J, Murray JJ, Nathan RA, et al. Fluticasone alone or in combination with salmeterol vs triamcinolone in asthma. Chest 1999;116:625-632.
12. van Noord JA, Schreurs AJ, Mol SJ, Mulder PG. Addition of salmeterol versus doubling the dose of fluticasone propionate in patients with mild to moderate asthma. Thorax 1999;54:207-212.
13. Pauwels RA, Lofdahl CG, Postma DS, et al , for the Formoterol and Corticosteroids Establishing Therapy (FACET) International Group Study. Effect of inhaled formoterol and budesonide on exacerbations of asthma. N Engl J Med 1997;337:1405-1411.
14. Juniper EF, Svensson K, O'Byrne PM, et al. Asthma quality of life during 1 year of treatment with budesonide with or without formoterol. Eur Respir J 1999;14:1038-1043.
15. Tattersfield AE, Postma DS, Barnes PJ, et al. Exacerbations of asthma: A descriptive study of 425 severe exacerbations. Am J Respir Crit Care Med 1999;160:594-599.
16. 2-agonist, assessed in airway biopsies and bronchoalveolar lavage in asthma. Am J Respir Crit Care Med 1999;160:1493-1499.
17. Sue-Chu M, Watlin A, Wilson S, et al. Bronchial biopsy study in asthmatics treated with low- and high-dose fluticasone propionate (FP) compared to low-dose FP combined with salmeterol. Eur Respir J 1999;14:1242S.
18. Kavuru M, Melamed J, Gross G, et al. Salmeterol and fluticasone propionate combined in a new powder inhalation device for the treatment of asthma: A randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol. In press.
19. Szefler SJ, Boushey HA, Pearlman DS, et al. Time to onset of effect of fluticasone propionate in patients with asthma. J Allergy Clin Immunol 1999;103(suppl 5, pt 1):780-788.
20. Nathan R, LaForce C, Mitchell D, et al. The salmeterol/fluticasone propionate combination (50/100 meg) via Diskus® has a rapid onset of effect in asthma patients on salmeterol or inhaled corticosteroids [abstract]. Am J Resp Crit Care Med 1999;159:A637.
21. Nathan R, Woodring A, Baitinger L, et al. The salmeterol/fluticasone propionate Diskus combination decreases the incidence of exacerbations compared to treatment with salmeterol or fluticasone propionate alone [abstract]. Eur Resp J 1999;14(suppl 30):123S. Abstract P848.
22. Shapiro G, Lumry W, Wolfe J, et al. Combined salmeterol 50 μg and fluticasone propionate 250 μg in the Diskus device for the treatment of asthma. Am J Crit Care Resp Med. In press.
23. Ukena D, Harnest U, Sakalauskas R, et al. Comparison of addition of theophylline to inhaled steroid with doubling of the dose of inhaled steroid in asthma. Eur Respir J 1997;10:2754-2760.
24. Evans DJ, Taylor DA, Zetterstrom O, Chung KF, O'Connor BJ, Barnes PJ. A comparison of low-dose inhaled budesonide plus theophylline and high-dose inhaled budesonide for moderate asthma. N Engl J Med 1997;337:1412-1418.
25. Davies B, Brooks G, Devoy M. The efficacy and safety of salmeterol compared to theophylline: Meta-analysis of nine controlled studies. Respir Med 1998;92:256-263.
26. Spector SL, Smith LJ, Glass M. Effects of 6 weeks of therapy with oral doses of ICI 204,219, a leukotriene D4 receptor antagonist, in subjects with bronchial asthma. ACCOLATE Asthma Trialists Group. Am J Respir Crit Care Med 1994;150:618-623.
27. Taniguchi Y, Tamura G, Honma M, et al. The effect of an oral leukotriene antagonist, ONO-1708, on allergen-induced immediate bronchoconstriction in asthmatic subjects. J Allergy Clin Immunol 1993;92:507-512.
28. Robuschi M, Riva E, Fuccella M, et al. Prevention of exercise-induced bronchoconstriction by a new leukotriene antagonist (SK&F 104353). A double-blind study versus disodium cromoglycate and placebo. Am Rev Respir Dis 1992;145:1285-1288.
29. Manning PJ, Watson RM, Margolskee DJ, Williams VC, Schwartz JI, O'Byrne PM. Inhibition of exercise-induced bronchoconstriction by MK-571, a potent leukotriene D4-receptor antagonist. N Engl J Med 1990;323:1736-1739.
30. Lofdahl CG, Reiss TF, Leff JA, et al. Randomised, placebo controlled trial of effect of a leukotriene receptor antagonist, montelukast, on tapering inhaled corticosteroids in asthmatic patients. BMJ 1999;319:87-90.
31. Tamaoki J, Kondo M, Sakai N, et al. Leukotriene antagonist prevents exacerbation of asthma during reduction of high-dose inhaled corticosteroid. Am J Respir Crit Care Med 1997;155:1235-1240.
32. Bateman ED, Holgate ST, Binks SM, Tams IP. A multicentre study to assess the steroid-sparing potential of Accolate™ (zafirlukast; 20 mg BD) [abstract]. Allergy 1995;50(suppl 26):320. Abstract P-0709.
33. Virchow JC, Hassell SM, Summerton L, Harris A. Improved asthma control over 6 weeks with zafirlukast in patients on high dose inhaled corticosteroids [abstract]. Eur Respir J 1997;10:437S. Abstract P2804.
34. Miyamoto T. Effects of zafirlukast on symptoms and pulmonary function of asthmatic patients with and without corticosteroids [abstract]. Eur Respir J 1999;14 (suppl 30):120S. Abstract P835.
35. Nayak AS, Anderson P, Charous BL, Williams K, Simonson S. Equivalence of adding zafirlukast versus double-dose inhaled corticosteroids in asthmatic patients symptomatic on low-dose inhaled corticosteroids [abstract]. J Allergy Clin Immunol 1998;101:S233.
36. Busse W, Nelson H, Wolfe J, Kalberg C, Yancey SW, Rickard KA. Comparison of inhaled salmeterol and oral zafirlukast in patients with asthma. J Allergy Clin Immunol 1999;103:1075-1080.